| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.0058 | 1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.001 | 1 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | -0.0011 | 1 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.00097 | 1 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.00099 | 1 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.0039 | 1 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | 0.00085 | 1 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.00078 | 1 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.00054 | 1 |
| mRNA | AMG-706 | FIMM | pan-cancer | AAC | -0.0022 | 1 |